The first participant in an investigational gene therapy trial of STXBP1 encephalopathy died, Capsida Biotherapeutics said. The death occurred days after dosing, according to information posted on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback